EUVIMEDEUVIMED entdecken
Open Access

Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer

Jianqiang Liang, Xuan Zhou, Lin Yuan, Tian Chen, Yicong Wan, Yi Jiang, Huangyang Meng, Mengting Xu, Lin Zhang, Wenjun Cheng

International Journal of Biological Sciences · 2024

DOI: 10.7150/ijbs.94568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Jianqiang Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Ovarian Neoplasms, Genomic Instability. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Large-scale phase III clinical trials of Olaparib have revealed benefits for ovarian cancer patients with BRCA gene mutations or homologous recombination deficiency (HRD). However, fewer than 50% of ovarian cancer patients have both BRCA mutations and HRD. Therefore, improving the effect of Olaparib in HR-proficient patients is of great clinical value. Here, a combination strategy comprising Olaparib and CDK12-IN-3 effectively inhibited the growth of HR-proficient ovarian cancer in cell line, patient-derived organoid (PDO), and mouse xenograft models. Furthermore, the combination strategy induced severe DNA double-strand break (DSB) formation, increased NHEJ activity in the G2 phase, and reduced HR activity in cancer cells. Mechanistically, the combination treatment impaired Ku80 poly(ADP-ribosyl)ation (PARylation) and phosphorylation, resulting in PARP1-Ku80 complex dissociation. After dissociation, Ku80 occupancy at DSBs and the resulting Ku80-primed NHEJ activity were increased. Owing to Ku80-mediated DNA end protection, MRE11 and Rad51 foci formation was inhibited after the combination treatment, suggesting that this treatment suppressed HR activity. Intriguingly, the combination strategy expedited cGAS nuclear relocalization, further suppressing HR and, conversely, increasing genomic instability. Moreover, the inhibitory effect on cell survival persisted after drug withdrawal. These findings provide a rationale for the clinical application of CDK12-IN-3 in combination with Olaparib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesOvarian NeoplasmsGenomic InstabilityFemaleHumansAnimalsCell Line, TumorMiceCell DeathCyclin-Dependent KinasesKu AutoantigenDNA Breaks, Double-Stranded

Stichwörter der Autor:innen

CDK12iHRNHEJOlaparibovarian cancer

Substanzen

olaparibPhthalazinesPiperazinesCDK12 protein, humanCyclin-Dependent KinasesKu Autoantigen

Autor:innen und Institutionen

  • Department of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China.

Zitieren

APA

Liang, J., Zhou, X., Yuan, L., Chen, T., Wan, Y., Jiang, Y., Meng, H., Xu, M., Zhang, L., & Cheng, W. (2024). Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.94568

Vancouver

Liang J, Zhou X, Yuan L, Chen T, Wan Y, Jiang Y, et al. Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer. International Journal of Biological Sciences. 2024. doi:10.7150/ijbs.94568

BibTeX
@article{Liang2024,
  author = {Liang, Jianqiang and Zhou, Xuan and Yuan, Lin and Chen, Tian and Wan, Yicong and Jiang, Yi and Meng, Huangyang and Xu, Mengting and Zhang, Lin and Cheng, Wenjun},
  title = {Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer},
  journal = {International Journal of Biological Sciences},
  year = {2024},
  doi = {10.7150/ijbs.94568}
}
Kostenlos starten →